Davita Inc. Announces New Value-Based Partnership with Humana Inc. to Expand Care for Patients with Chronic Kidney Disease

Berkshire Hathaway's largest proportional holding is in DaVita (DVA), a kidney dialysis center operator, with a 45% stake. Berkshire has reduced its position from 36.1 million to 28.7 million shares since early 2025. DaVita's stock is up 56% year-to-date, with Q1 revenue of $3.4 billion and adjusted profit of $198 million. The company raised its EPS guidance to $14.10-$15.20.

Berkshire Hathaway (BRK.A, BRK.B) shifted to net stock buying in Q2 2026, contrasting Warren Buffett's cash-hoarding stance. Under Greg Abel, it bought Alphabet ($17B), Delta ($1.64B), Lennar ($273M), and Macy's ($101M), while selling Bank of America ($1.7B) and others. Buffett still views the market as overvalued, per a May CNBC interview.

UnitedHealth Group reported $5B in Q2 net income, with a declining medical care ratio. Shares of UnitedHealth, CVS Health, Centene, and Humana have risen significantly. Centene and Humana reported strong earnings, while Humana plans to exit some markets in 2027. Oscar Health entered new markets and saw its stock triple in six months.

Shares of Centene (CNC), UnitedHealth (UNH), CVS (CVS), and Humana (HUM) fell after-hours Tuesday after a report that the Trump administration plans to end a $3.6B federal subsidy for Medicare Part D plans post-2026. The subsidy helps keep premiums low for 25M enrollees. The loss of support could pressure margins and enrollment for insurers offering stand-alone Part D plans, though some beneficiaries may shift to Medicare Advantage plans.

Glenmark Pharmaceuticals said its U.S. subsidiary, Glenmark USA, agreed to settle with Humana Inc. for $15.28 million, including interest, to resolve antitrust and consumer protection claims over alleged generic drug price-fixing and market allocation. Glenmark USA denies all allegations. The company said the amount is already provided for in its financials and expects no significant financial impact.

Glenmark Pharmaceuticals’ U.S. unit said, in an exchange filing, it reached a settlement with Humana to resolve antitrust litigation tied to consolidated generic-drug price-fixing claims in the Eastern District of Pennsylvania. The settlement totals $15.28 million plus interest, paid in two installments. Glenmark denied the allegations and said the amount was already booked in its financial statements.